Boston Scientific (BSX) Tops Q4 EPS by 2c, FY EPS Guidance Trails Views at Mid-Point
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Boston Scientific (BSX) Tops Q4 EPS by 2c, FY EPS Guidance Trails Views at Mid-Point
February 7, 2019 8:06 AM EST
Credit Suisse analyst Matt Miksic raised the price target on Boston Scientific (NYSE: BSX) to $45.00 (from $42.00) while maintaining a Outperform rating following the company's 4Q earnings report. Organic sales growth guidance for 2019 is 7-8.5%. EPS guidance for 2019 is $1.53-1.58, which includes dilution recent... More
February 7, 2019 7:25 AM EST
Raymond James analyst Jayson Bedford raised the price target on Boston Scientific (NYSE: BSX) to $45.00 (from $42.00) while maintaining a Strong Buy rating.
"... we ultimately believe this guidance will prove conservative (similar to prior years) and believe the dizzying (in a good way) amount of new products should drive 8%+ organic growth."
...
More
February 6, 2019 1:37 PM EST
Jefferies analyst Raj Denhoy raised the price target on Boston Scientific (NYSE: BSX) to $44.00 (from $43.00) while maintaining a Buy rating.
...
More
February 6, 2019 1:00 PM EST
Piper Jaffray analyst Matt O'Brien raised the price target on Boston Scientific (NYSE: BSX) to $42.00 (from $40.00) while maintaining a Overweight rating.
O'Brien said the strong revenue guidance trumps slightly below Street EPS outlook.
...
More
